Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Agorastos, Theodoros ^a   Chatzistamatiou, Kimon ^a   Katsamagkas, Taxiarchis ^a   Koliopoulos, George ^b   Daponte, Alexandros ^c   Constantinidis, Theocharis ^d   Constantinidis, Theodoros C ^e  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

^d Ministry of Health   (Greece)

^e DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BIOPSY BRUSH; CANCER RISK; CANCER SCREENING; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPING TECHNIQUE; GREECE; GREEK (PEOPLE); HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PREVALENCE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; BIOPSY; CANCER GRADING; CANCER STAGING; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; CYTOLOGY; EARLY CANCER DIAGNOSIS; GENETICS; MIDDLE AGED; REPRODUCIBILITY; RISK FACTOR; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

ADULT; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CYTOLOGICAL TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; GENOTYPING TECHNIQUES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84925597699     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119755     Document Type: Article

References (66)

1. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ. 1999; 318: 904-908. PMID: 10102852
2. Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS One. 2010; 5: e9584. doi: 10.1371/journal.pone.0009584 PMID: 20231893
3. Koss LGThe Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA. 1989; 261: 737-743. PMID: 2642983
4. Bosch FX, Munoz N, Shah KV, Meheus A. Second International Workshop on the Epidemiology of Cervical Cancer and Human Papillomaviruses. Int J Cancer. 1992; 52: 171-173. PMID: 1325948
5. zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol. 1977; 78: 1-30. PMID: 202434
6. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of pathology. 1999; 189: 12-19. PMID: 10451482
7. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst. 2003;Monogr: 3-13.
8. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009; 10: 321-322. PMID: 19350698
9. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004; 110: 94-101.PMID: 15054873
10. Stoler MH, Wright TC, Sharma A, Apple R, Gutekunst K, Wright TL, et al. High-Risk Human Papillomavirus Testing in Women With ASC-US Cytology: Results From the ATHENA HPV Study. American Journal of Clinical Pathology. 2011; 135: 468-475. doi: 10.1309/AJCPZ5JY6FCVNMOT PMID: 21350104
11. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: A subanalysis of the ATHENA study. Lancet Oncol. 2011; 12: 880-890. doi: 10.1016/S1470-2045(11)70188-7 PMID: 21865084
12. Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL, et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011; 136: 578-586. doi: 10.1309/AJCPTUS5EXAS6DKZ PMID: 21917680
13. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012; 206: 46 e41-46 e11. doi: 10.1016/j.ajog.2011.07.024 PMID: 21944226
14. Dillner J. Primary human papillomavirus testing in organized cervical screening. Curr Opin Obstet Gynecol. 2013; 25: 11-16. doi: 10.1097/GCO.0b013e32835c5d10 PMID: 23299089
15. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383: 524-532. doi: 10.1016/S0140-6736(13)62218-7 PMID: 24192252
16. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: A meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004; 96: 280-293. PMID: 14970277
17. Agorastos T, Dinas K, Lloveras B, de Sanjose S, Kornegay JR, Bonti H, et al. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. Gynecologic oncology. 2005; 96: 714-720. PMID: 15721416
18. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357: 1579-1588. PMID: 17942871
19. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009; 101: 1612-1623. doi: 10.1093/jnci/djp367 PMID: 19903804
20. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119: 1095-1101. PMID: 16586444
21. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009; 360: 1385-1394. doi: 10.1056/NEJMoa0808516 PMID: 19339719
22. Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study. Int J Cancer. 2008; 122: 2294-2300. doi: 10.1002/ijc.23339 PMID: 18240149
23. Elfstrom KM, Smelov V, Johansson AL, Eklund C, Naucler P, Arnheim-Dahlstrom L, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ. 2014; 348: g130. doi: 10.1136/bmj.g130 PMID: 24435414
24. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 97: 1072-1079. PMID: 16030305
25. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. The lancet oncology. 2010; 11: 1048-1056. doi: 10.1016/S1470-2045(10)70230-8 PMID: 20952254
26. Schiffman M, Burk RD, Boyle S, Raine-Bennett T, Katki HA, Gage JC, et al. A Study of Genotyping for the Management of Human Papillomavirus-Positive, Cytology-Negative Cervical Screening Results. J Clin Microbiol. 2015; 53(1):52-9. doi: 10.1128/JCM.02116-14 PMID: 25339396
27. Wang SS, Gonzalez P, Yu K, Porras C, Li Q, Safaeian M, et al. Common genetic variants and risk for HPV persistence and progression to cervical cancer. PLoS One. 2010; 5: e8667. doi: 10.1371/journal. pone.0008667 PMID: 20084279
28. Roura E, Castellsague X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. Int J Cancer. 2014; 135: 453-466. doi: 10.1002/ijc.28666 PMID: 24338632
29. Bulk S, Bulkmans NW, Berkhof J, Rozendaal L, Boeke AJ, Verheijen RH, et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer. 2007; 121: 361-367. PMID: 17354241
30. Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev. 2011; 20: 1398-1409. doi: 10.1158/1055-9965.EPI-11-0206 PMID: 21602310
31. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E, et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and metaanalysis of non-randomized studies. Gynecol Oncol. 2007; 104: 232-246. PMID: 17084886
32. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002; 287: 2114-2119. PMID: 11966386
33. Agorastos T, Koutkias V, Falelakis M, Lekka I, Mikos T, Delopoulos A, et al. Semantic integration of cervical cancer data repositories to facilitate multicenter association studies: the ASSIST approach. Cancer Inform. 2009; 8: 31-44. PMID: 19458792
34. Bornstein J, Bentley J, Bosze P, Girardi F, Haefner H, Menton M, et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol. 2012; 120: 166-172. PMID: 22914406
35. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): A randomised controlled trial. Lancet Oncol. 2009; 10: 672-682. doi: 10.1016/S1470-2045(09)70156-1 PMID: 19540162
36. Schmidt CO, Kohlmann T. When to use the odds ratio or the relative risk? Int J Public Health. 2008; 53: 165-167. PMID: 19127890
37. Wilber ST, Fu R. Risk ratios and odds ratios for common events in cross-sectional and cohort studies. Acad Emerg Med. 2010; 17: 649-651. doi: 10.1111/j.1553-2712.2010.00773.x PMID: 20624147
38. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003; 138: W1-12. PMID: 12513067
39. Sherman ME, Schiffman M, Cox JT. Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study G Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/ Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst. 2002; 94: 102-107. PMID: 11792748
40. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008; 148: 493-500. PMID: 18378945
41. Traut HF, Papanicolaou GN. Cancer of the Uterus: The Vaginal Smear in Its Diagnosis. Cal West Med. 1943; 59: 121-122. PMID: 18746585
42. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004; 364: 249-256. PMID: 15262102
43. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human pap-illomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26: Suppl. 2008; 10: K29-41. doi: 10.1016/j.vaccine.2008.06.019 PMID: 18847555
44. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J, et al. Liquid compared with conventional cervical cytology: A systematic review and meta-analysis. Obstet Gynecol. 2008; 111: 167-177. doi: 10.1097/01.AOG.0000296488.85807.b3 PMID: 18165406
45. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011; 103: 368-383. doi: 10.1093/ jnci/djq562 PMID: 21282563
46. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137: 516-542. doi: 10.1309/AJCPTGD94EVRSJCG PMID: 22431528
47. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007; 357: 1589-1597. PMID: 17942872
48. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial. Lancet Oncol. 2010; 11: 249-257. doi: 10.1016/S1470-2045(09) 70360-2 PMID: 20089449
49. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012; 30 Suppl 5: F88-99. doi: 10. 1016/j.vaccine.2012.06.095 PMID: 23199969
50. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012; 13: 78-88. doi: 10.1016/ S1470-2045(11)70296-0 PMID: 22177579
51. Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst. 2014; 106(8).
52. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res. 2009; 40: 478-485. doi: 10.1016/j.arcmed.2009.06.003 PMID: 19853188
53. Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, et al. Comparing the performance of six human papillomavirus tests in a screening population. British journal of cancer. 2013; 108: 908-913. doi: 10.1038/bjc.2013.22 PMID: 23370211
54. Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, Daalmeijer NF, et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol. 2011; 49: 3983-3985. doi: 10.1128/JCM.05552-11 PMID: 21880968
55. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013; 208: 184 e181-184 e111. doi: 10.1016/j.ajog.2012.11.020 PMID: 23174289
56. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009; 124: 516-520. doi: 10.1002/ijc.24010 PMID: 18973271
57. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: A populationbased study in routine clinical practice. Lancet Oncol. 2011; 12: 663-672. doi: 10.1016/S1470-2045 (11)70145-0 PMID: 21684207
58. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007; 11: 201-222. PMID: 17917566
59. Kinney W, Fetterman B, Cox JT, Lorey T, Flanagan T, Castle PE, et al. Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. Gynecol Oncol. 2011; 121: 309-313. doi: 10.1016/j.ygyno.2010.12.361 PMID: 21276605
60. Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess. 2014; 18: 1-196.
61. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol. 2000; 19: 1-5. PMID: 11091143
62. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518-527. PMID: 12571259
63. Agorastos T, Lambropoulos AF, Sotiriadis A, Mikos T, Togaridou E, Emmanouilides CJ, et al. Prevalence and distribution of high-risk human papillomavirus in Greece. Eur J Cancer Prev. 2009; 18: 504-509. doi: 10.1097/CEJ.0b013e32832abd5e PMID: 19741545
64. Agorastos T, Chatzistamatiou K, Zafrakas M, Siamanta V, Katsamagkas T, Constantinidis TC, et al. Epidemiology of HPV infection and current status of cervical cancer prevention in Greece: final results of the LYSISTRATA cross-sectional study. Eur J Cancer Prev. 2014; 23: 425-431. doi: 10.1097/CEJ. 0000000000000060 PMID: 24977385
65. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A metaanalysis. Lancet Infect Dis. 2007; 7: 453-459. PMID: 17597569
66. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202: 1789-1799. doi: 10.1086/657321 PMID: 21067372